CHAMPIONS ONCOLOGY, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$426.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-11.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-09-11
- CHAMPIONS ONCOLOGY, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-07-31 was -$426.00K.
- CHAMPIONS ONCOLOGY, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-04-30 was -$667.00K.
- CHAMPIONS ONCOLOGY, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-01-31 was -$278.00K, a 106.18% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-10-31 was $237.00K, a 67.45% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2026 was -$1.18M, a 124.99% decline from fiscal 2025.
- CHAMPIONS ONCOLOGY, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was $4.70M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$426.00K 10-Q · filed 2026-09-11 | -$1.09M derived: sum of 2 quarters · filed 2026-09-11 | -$1.37M derived: sum of 3 quarters · filed 2026-09-11 | -$1.13M derived: sum of 4 quarters · filed 2026-09-11 |
| 2026-04-30 | -$667.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | -$945.00K derived: sum of 2 quarters · filed 2026-07-27 | -$708.00K derived: sum of 3 quarters · filed 2026-07-27 | -$1.18M 10-K · filed 2026-07-27 |
| 2026-01-31 | -$278.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-12 | -$41.00K derived: sum of 2 quarters · filed 2026-03-12 | -$508.00K 10-Q · filed 2026-03-12 | -$2.34M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-10-31 | $237.00K 10-Q · filed 2026-03-12 | -$230.00K 10-Q · filed 2025-12-15 | -$2.06M derived: sum of 3 quarters · filed 2026-09-11 | $2.43M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-07-31 | -$466.00K 10-Q · filed 2026-09-11 | -$2.30M derived: sum of 2 quarters · filed 2026-09-11 | $2.19M derived: sum of 3 quarters · filed 2026-09-11 | $2.92M derived: sum of 4 quarters · filed 2026-09-11 |
| 2025-04-30 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-27 | $2.66M derived: sum of 2 quarters · filed 2026-07-27 | $3.39M derived: sum of 3 quarters · filed 2026-07-27 | $4.70M 10-K · filed 2026-07-27 |
| 2025-01-31 | $4.50M 10-Q · filed 2026-03-12 | $5.22M derived: sum of 2 quarters · filed 2026-03-12 | $6.54M 10-Q · filed 2026-03-12 | |
| 2024-10-31 | $728.00K 10-Q · filed 2026-03-12 | $2.04M 10-Q · filed 2025-12-15 | ||
| 2024-07-31 | $1.31M 10-Q · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |